Technological aspects of the “Probioskin” emulgel development
DOI:
https://doi.org/10.24959/nphj.22.88Keywords:
technology; block diagram; emulgel; probiotics; dermatological diseasesAbstract
Aim. To develop a rational technology of a new semisolid preparation for skin application with a probiotic component in the form of an emulgel under the conditional name “Probioskin”.
Materials and methods. When developing the technology the study objects were emulgel samples with selected substances – a lyophilized biomass of lactobacilli, dexpanthenol, lactic acid, and excipients – Aristoflex AVC gelling agent, propylene glycol, polysorbate-80, tocopherol, peach oil. To control the quality of the samples, the requirements of the monograph of the SPhU 2.4 on dosage forms “Semi-solid preparations for dermal use” and the general monograph of the SPhU 2.5 “Viable biotherapeutic drugs for human use” were observed.
Results and discussion. The process of production of the “Probioskin” drug developed is carried out in the premises of purity class C according to the standard flowchart: the stage of auxiliary works, the stage of the main technological process, the stage of packaging, labeling and shipment of the finished product. The sequence of the technological stages in accordance with the technology of production of a semisolid preparation for skin application – the “Probioskin” emulgel consists of 8 stages: preparation of the raw material, preparation of an oil concentrate of a probiotic component, preparation of an aqueous concentrate of active substances, preparation of a gel base, preparation of an emulsion, packaging of tubes in packs, packaging of packs in group container. The specification for the “Probioskin” drug includes the following sections: “Description”, “Identification”, “pH”, “Uniformity”, “Mass of packaging contents”, “Microbiological
purity”, “Assay”. The results of control of the finished product meet the requirements of the MQC.
Conclusions. Based on the complex of physicochemical, microbiological, biopharmaceutical, technological, rheological studies, a rational technology of a semisolid preparation for skin application under the conditional name “Probioskin”
in the form of an emulgel has been developed. The indicators of quality, permissible norms, methods of control and critical parameters of production of the product developed have been determined.
References
Requena T., Velasco M. The human microbiome in sickness and in health. Revista Clínica Española (English Edition). 2020.Vol. 221, Iss. 4. P. 233–240. DOI: https://doi.org/10.1016/j.rceng.2019.07.018.
França K. Topical Probiotics in Dermatological Therapy and Skincare: A Concise Review. Dermatology and Therapy (Heidelb). 2020. Vol. 11. P. 71–77. DOI: https://doi.org/1007/s13555-020-00476-7.
Sebum and hydration levels in specific regions of human face significantly predict the nature and diversity of facial skin microbiome / S. Mukherjee et al. Scientific Reports. 2016. Vol. 6. P. 36062. DOI: https://doi.org/10.1038/srep36062.
Microbiome in healthy skin, update for dermatologists / B. Dréno et al. Journal of the European Academy of Dermatology and Venereology. 2016. Vol. 30, Iss. 12. P. 2038–2047. DOI: https://doi.org/10.1111/jdv.13965.
Izawa N., Sone T. Cosmetic Ingredients Fermented by Lactic Acid Bacteria. Microbial Production. 2014. P. 233–242. DOI: https://doi. org/10.1007/978-4-431-54607-8_20.
Use of probiotics for dermal application / B. Cinque et al. Probiotics: Biology, Genetics and Health Aspects. 2011. Vol. 21. P. 221–241. DOI: https://doi.org/10.1007/978-3-642-20838-6_9.
Державна фармакопея України. Доповнення 4 / ДП «Український науковий фармакопейний центр якості лікарських засобів». 2-е вид. Харків : ДП «Український науковий фармакопейний центр якості лікарських засобів», 2020. 600 с.
Державна фармакопея України. Доповнення 5 / ДП «Український науковий фармакопейний центр якості лікарських засобів». 2-е вид. Харків : ДП «Український науковий фармакопейний центр якості лікарських засобів», 2021. 424 с.
The main stages of pharmaceutical development of emulgel “Probioskin” / A. Soloviova et al. Scientific Journal «ScienceRise: Pharmaceutical Science». 2021. № 6 (34). P. 75–84. DOI: https://doi.org/10.15587/2519-4852.2021.249710.
Soloviova A., Kukhtenko H., Kaliuzhnaia O. Substantiation of the composition of a semi-solid dosage form with a probiotic component for use in dermatology. EUREKA: Health Sciences. 2021. № 6. P. 54–63. DOI: https://doi.org/10.21303/2504-5679.2021.002181.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
